Black and Hispanic patients with MCC are more likely to have tumors on UV-protected sites, which is associated with better outcomes.
Ixekizumab was more effective for the treatment of mild to moderate psoriasis vs severe psoriasis at most time points through 52 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback